1160950-71-9

Upstream product

• 223718-30-7 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one 
• 1334628-88-4 C₂₀H₁₇NO₆ 
• 1160952-36-2 C₂₇H₂₃NO₇ 
• 1350834-62-6 C₁₂H₁₁NO₄ 
• 1083313-80-7 3',6-dimethoxy-[1,1'-biphenyl]-3-carbonyl chloride 
• 1083313-05-6 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid 

Downstream Products

• 1160950-89-9 3',6-dimethoxy-N-(8-methyl-2-oxo-7-(1,2,3,6-tetrahydropyridin-3-yloxy)-2H-chromen-3-yl)biphenyl-3-carboxamide 
• 1160950-91-3 N-(7-(1-acetyl-1,2,3,6-tetrahydropyridin-3-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1160950-90-2 3',6-dimethoxy-N-(8-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-3-yloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide 
• 1160951-12-1 N-(7-(1-acetylpiperidin-3-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-39-5 3',6-dimethoxy-N-(8-methyl-7-(2-(methylamino)ethoxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide 
• 1160951-48-3 N-(7-(2,3-dihydroxypropoxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1160951-81-4 N-(7-((2R,3R,4R,6S)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-04-4 N-(7-((2S)-3,4-dihydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-08-8 N-(7-(3-hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-09-9 N-(7-(3-hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-11-3 N-(7-(4-hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-12-4 N-(7-(4-hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide 
• 1308889-66-8 C₄₁H₄₁NO₁₀ 
• 1308889-13-5 C₃₂H₂₉NO₁₀ 

Relevant academic research and scientific papers

Exploiting polarity and chirality to probe the Hsp90 C-terminus

Inhibition of the Hsp90 C-terminus is an attractive therapeutic approach for the treatment of cancer. Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically complex noviose sugar that has limited the generation of structure-

Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents

Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ?700- fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure- activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.